Leerink notes that Outperform-rated Intuitive Surgical (ISRG) has received CE mark for da Vinci 5 across a variety of surgical procedures. This approval comes slightly ahead of prior management commentary suggesting CE mark near year-end 2025, the firm adds. Leerink views this as an incremental positive with the potential for greater-than-expected outside-U.S. DV5 contribution in the second half of 2025, though it thinks the degree to which Intuitive’s outside-U.S. DV5 launch will prove to be a meaningful near-term growth driver in Europe compared to its strong initial success following its launch in the U.S. remains unclear.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)
- Intuitive Surgical’s Strong Market Position and Future Prospects Justify Buy Rating Despite Remanufacturing Concerns
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories
- Deutsche Bank Sounds Alarm on Intuitive Surgical Stock (ISRG) with a Rare ‘Sell’ Rating